SynthesisFrontiers in pharmacology2025
Systematic review and meta-analysis of propranolol in the prevention and treatment of post-traumatic stress disorder.
Synthesis in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Psychological Scars and Physical Consequences: Linking PTSD to Cardiovascular Health.Journal of cardiovascular translational research · 2026Review
- β-Adrenergic Signaling Contributes to Circadian and Lipid Dysregulation in Meibomian Glands During Chronic Psychological Stress.Investigative ophthalmology & visual science · 2026Article
- Advances in time-sensitive assessment and intervention for acute stress reaction.Frontiers in psychology · 2026Review
- Biomarkers and Mechanisms of Cardiovascular Susceptibility and Resilience to Post-Traumatic Stress Disorder.Reviews in cardiovascular medicine · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: This systematic review and meta-analysis aim to comprehensively evaluate the efficacy of propranolol in the prevention and treatment of post-traumatic stress disorder (PTSD), with a focus on its improvement of core PTSD symptoms. Methods: A literature search was conducted across multiple databases (including PubMed, Cochrane, Web of Science, and Embase), with the search cutoff date in October 2024. The studies included randomized controlled trials (RCTs) investigating pharmacological treatments for PTSD. PTSD symptoms were assessed using standardized clinical scales, including the Clinician-Administered PTSD Scale (CAPS) and the PTSD Checklist (PCL). The primary outcome was the improvement in PTSD symptoms. Results: Seven studies met the inclusion criteria for the meta-analysis. The studies showed low heterogeneity, with a chi-squared value of 2.56 (df = 6, p = 0.86) and I Conclusion: This systematic review and meta-analysis provide preliminary evidence supporting the possible role of propranolol in alleviating PTSD symptoms. Future researches are needed to further clarify the therapeutic potential, mechanisms of action, and long-term safety of propranolol in PTSD treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.